在用静脉内注射治疗的视网膜疾病中停止治疗的原因
Alaa Din Abdin1, Nicolas Barakat1, Wissam Aljundi1
1Department of Ophthalmology, Saarland University Medical Center UKS, Homburg/Saar, Germany.
概括
预后不佳是导致视网膜疾病中断静脉注射 (IVI) 的主要原因. 诸如年龄增长和视力恶化等因素会影响患者对IVI治疗的坚持.
科学领域:
- 眼科 眼科
- 视网膜疾病
- 医学治疗
背景情况:
- 静脉内注射 (IVI) 是各种视网膜疾病的常见治疗方法.
- 了解停止治疗对于优化患者的治疗结果至关重要.
研究的目的:
- 在患有视网膜疾病的患者中,确定停止静脉注射 (IVI) 的主要原因.
- 分析导致IVI治疗不持续的因素.
主要方法:
- 一项回顾性研究分析了2016年1月至2024年1月期间接受IVI治疗的2218名患者的数据.
- 治疗停止的原因被记录下来,包括患者的不持续性 (治疗下降).
- 与其他患者进行了比较,以确定影响因素.
主要成果:
- 治疗停止的最常见原因是预后不佳 (视力敏度<1. 3 logMAR).
- 其他原因包括改变医疗中心 (7.9%),并发性全身性疾病 (5.7%) 和失去联系 (5.7%).
- 拒绝治疗 (不持续治疗) 的患者年龄较大,视力敏度较差,注射次数较多,并且更有可能接受预先注射方案.
结论:
- 黄斑疾病固有的预后不佳是停止治疗的主要原因.
- 诸如晚年,注射频率增加,预测方案和视力下降等因素导致患者不坚持使用IVI.
- 识别这些因素可以帮助改善视网膜疾病的坚持和长期治疗.
相关概念视频
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K


